Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Does this not looking more and more that the BTD (Breakthrough Therapy Designation) for apabetalone favours CHF for patients with CKD and T2DM in combination with standard of care (including statins) for secondary prevention of MACE?
